Literature DB >> 15790617

Highly active antiretroviral therapy.

Rita Murri.   

Abstract

Mesh：

Year:  2005        PMID： 15790617      PMCID： PMC555616          DOI： 10.1136/bmj.330.7493.681

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  How does expert advice impact genotypic resistance testing in clinical practice?

Authors:  Sheila M Badri; Oluwatoyin M Adeyemi; Blake E Max; Brandon M Zagorski; David E Barker
Journal:  Clin Infect Dis       Date:  2003-08-15       Impact factor: 9.079

2.  Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.

Authors:  A Ammassari; R Murri; P Pezzotti; M P Trotta; L Ravasio; P De Longis; S Lo Caputo; P Narciso; S Pauluzzi; G Carosi; S Nappa; P Piano; C M Izzo; M Lichtner; G Rezza; A Monforte; G Ippolito; M d'Arminio Moroni; A W Wu; A Antinori
Journal:  J Acquir Immune Defic Syndr       Date:  2001-12-15       Impact factor: 3.731

3.  Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group.

Authors:  A C Justice; L Rabeneck; R D Hays; A W Wu; S A Bozzette
Journal:  J Acquir Immune Defic Syndr       Date:  1999-06-01       Impact factor: 3.731

4.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

Authors:  A d'Arminio Monforte; A C Lepri; G Rezza; P Pezzotti; A Antinori; A N Phillips; G Angarano; V Colangeli; A De Luca; G Ippolito; L Caggese; F Soscia; G Filice; F Gritti; P Narciso; U Tirelli; M Moroni
Journal:  AIDS       Date:  2000-03-31       Impact factor: 4.177

5.  Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.

Authors:  Caroline A Sabin; Teresa Hill; Fiona Lampe; Ryanne Matthias; Sanjay Bhagani; Richard Gilson; Mike S Youle; Margaret A Johnson; Martin Fisher; George Scullard; Philippa Easterbrook; Brian Gazzard; Andrew N Phillips
Journal:  BMJ       Date:  2005-03-04

6.  Effect of persistent moderate viremia on disease progression during HIV therapy.

Authors:  Stephen P Raffanti; Jennifer S Fusco; Beth H Sherrill; Nellie I Hansen; Amy C Justice; Richard D'Aquila; Wendy J Mangialardi; Gregory P Fusco
Journal:  J Acquir Immune Defic Syndr       Date:  2004-09-01       Impact factor: 3.731

7.  Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates.

Authors:  David R Bangsberg; Travis C Porco; C Kagay; Edwin D Charlebois; Steven G Deeks; David Guzman; Richard Clark; Andrew Moss
Journal:  J Infect Dis       Date:  2004-06-09       Impact factor: 5.226

8.  Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Authors:  Peter W Hunt; Steven G Deeks; Benigno Rodriguez; Hernan Valdez; Starley B Shade; Donald I Abrams; Mari M Kitahata; Melissa Krone; Torsten B Neilands; Richard J Brand; Michael M Lederman; Jeffrey N Martin
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

9.  Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

Authors:  Felipe García; Elisa de Lazzari; Montserrat Plana; Pedro Castro; Gabriel Mestre; Meritxell Nomdedeu; Emilio Fumero; Esteban Martínez; Josep Mallolas; José L Blanco; José M Miró; Tomás Pumarola; Teresa Gallart; José M Gatell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-06-01       Impact factor: 3.731

10.  Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.

Authors:  Bruno Ledergerber; Jens D Lundgren; A Sarah Walker; Caroline Sabin; Amy Justice; Peter Reiss; Cristina Mussini; Ferdinand Wit; Antonella d'Arminio Monforte; Rainer Weber; Gregory Fusco; Schlomo Staszewski; Matthew Law; Robert Hogg; Fiona Lampe; M John Gill; Francesco Castelli; Andrew N Phillips
Journal:  Lancet       Date:  2004 Jul 3-9       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.